4A10 antibody therapy (Allterum Therapeutics)

N/A

Report date: 2024/06/04 16:17:36

Base Information

Drug Name4A10 antibody therapy (Allterum Therapeutics)
Drug Alias Nameanti-IL-7R alpha mAbanti-interleukin-7 receptor alpha monoclonal antibody4A104A-10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Interleukin-7 receptor subunit alpha
TargetsInterleukin-7 receptor subunit alpha
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of Health
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A